Company Filing History:
1 out of 1,536 
1 out of 133 Years Active: 1997-2002
Title: Uwe Bamberger: Innovator in Antibody and Pharmaceutical Research
Introduction
Uwe Bamberger is a notable inventor based in Ochsenhausen, Germany. He has made significant contributions to the fields of antibody development and pharmaceutical research. With a total of 2 patents, his work has had a considerable impact on medical science.
Latest Patents
Bamberger's latest patents include a FAPα-specific antibody with improved producibility. This invention provides recombinant antibody proteins that specifically bind to fibroblast activation protein alpha (FAPα). The framework modifications result in enhanced producibility in host cells. Additionally, the invention encompasses the use of these antibodies for diagnostic and therapeutic purposes, along with methods for their production. Another significant patent involves trisubstituted pyrimido [5,4-d] pyrimidines, which are designed for modulating multi-drug resistance. These compounds possess valuable pharmacological properties, particularly in chemotherapy, where they can sensitize resistant tumors.
Career Highlights
Throughout his career, Uwe Bamberger has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Boehringer Ingelheim International GmbH and Dr. Karl Thomae GmbH. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Bamberger has collaborated with esteemed colleagues, including John Edward Park and Pilar Garin-Chesa. These partnerships have fostered innovation and have been instrumental in the success of his research endeavors.
Conclusion
Uwe Bamberger's contributions to antibody and pharmaceutical research highlight his role as an influential inventor. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.